Ultragenyx Pharmaceutical

RARE

Market cap $2.98B

RARE Hedge Fund Activity: Q3 2016 in Review

172 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2016, worth a combined $2.79B — up 54% from $1.81B a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new RARE positions and 15 closed out — a net gain of 12 holders — while 67 added to existing stakes and 56 trimmed.

The largest buyer was Capital Guardian Trust, opening a new position worth an estimated $31.5M. The largest seller was Wells Fargo, cutting an estimated $39.1M.

• 172 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2016, up from 161 in Q2 2016.
• Funds reported $2.79B of Ultragenyx Pharmaceutical stock for Q3 2016, up 54% quarter-over-quarter.
• 27 funds opened new Ultragenyx Pharmaceutical positions in Q3 2016 and 15 closed out, a net change of +12 holders.
• The largest Ultragenyx Pharmaceutical buyer in Q3 2016 was Capital Guardian Trust, an estimated $31.5M added.
• The largest Ultragenyx Pharmaceutical seller in Q3 2016 was Wells Fargo, an estimated $39.1M sold.

Based on aggregated 13F filings for Q3 2016.